NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research

Nyrada Inc. (ASX: NYR) has had its NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research, a highly regarded publication which covers the research of new cholesterol drugs. Nyrada is developing an oral PCSK9 inhibitor drug as a convenient and cost competitive alternative to injectable PCSK9 inhibitors, to be taken with or without a statin aimed at reducing LDL cholesterol in patients.

Nyrada’s NYX-PCSK9i Efficacy Study was the first to show combination treatment of a small-molecule PCSK9 inhibitor and a statin is highly effective in lowering LDL (“bad”) cholesterol. PCSK9 has been clinically validated as a therapeutic target for the treatment of hypercholesterolemia and atherosclerosis, both of which are leading contributors to cardiovascular disease.

The company’s Chief Scientific Officer, Dr. Benny Evison stated, “It is pleasing that the significant cholesterol lowering result achieved in this study has been recognised by the Journal of Lipid Research. The paper was reviewed and approved by independent experts in the field, so their recommendation to publish indicates our science is sufficiently rigorous and novel to warrant inclusion in such a well-respected journal.”

Canary Capital believes that publication in such a highly regarded journal adds to the credibility of the company’s cholesterol drug development program. The Phase I first in human clinical trial is scheduled to get underway during the first half of 2023.